Effect of biologically active coating on biocompatibility of Nitinol devices designed for the closure of intra-atrial communications

被引:38
作者
Kong, XQ
Grabitz, RG
van Oeveren, W
Klee, D
van Kooten, TG
Freudenthal, F
Qing, M
von Bernuth, G
Seghaye, MC
机构
[1] Rhein Westfal TH Aachen, Dept Paediat Cardiol, Aachen, Germany
[2] Univ Groningen, Dept Biomed Engn, NL-9700 AB Groningen, Netherlands
[3] Rhein Westfal TH Aachen, Inst Macromol & Text Chem, Aachen, Germany
关键词
Nitinol; biologically active coating; thrombogenicity; endothelialisation;
D O I
10.1016/S0142-9612(01)00304-0
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Anti-thrombogenicity and rapid endothelialisation are prerequisites for the use of closure devices of intra-atrial communications in order to reduce the risk of cerebral embolism. The purpose of this study was therefore to assess the effect of bioactive coatings on biocompatibility of Nitinol coils designed for the closure of intra-atrial communications. Nitinol coils (it = 10, each) and flat Nitinol bands (n = 3, each) were treated by basic coating with poly(amino-p-xylytene-co-p-xylylene) and then coated with either heparin, r-hirudin or fibronectin. Anti-thrombogenicity was studied in vitro in a dynamic model with whole blood by partial thromboplastin time (PTT), platelet binding and thrombin generation, respectively, and cytotoxicity by hemolysis. Endothelialisation was studied on Nitinol bands with human umbilical venous endothelial cells (HUVEC) by 3-(4,5-dimethylthiazole-2yl)-2,5-triphenyl tetrazolium (MTT) assay and immunofluorescence analysis of Ki67, vinculin, fibronectin and von Willebrand Factor. Uncoated or coated devices did not influence hemolysis and PTT, r-Hirudin (but not heparin) and fibronectin coating showed lower platelet binding than uncoated Nitinol (p < 0.005, respectively). Heparin and r-hirudin coating reduced thrombin formation (p < 0.05 versus Nitinol, respectively). HUVEC adhesion, proliferation, and matrix formation decreased in the order: fibronectin coating > uncoated Nitinol > r-hirudin coating > heparin coating > basic coating, MTT assay corroborated these findings. In conclusion, r-hirudin and fibronectin coating, by causing no acute cytotoxicity, decreasing thrombogenicity and increasing endothelialisation improve in vitro biocompatibility of Nitinol devices designed for the closure of intra-atrial communications. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1775 / 1783
页数:9
相关论文
共 29 条
[1]   All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells [J].
Axel, DI ;
Frigge, A ;
Dittmann, J ;
Runge, H ;
Spyridopoulos, I ;
Riessen, R ;
Viebahn, R ;
Karsch, KR .
CARDIOVASCULAR RESEARCH, 2001, 49 (04) :851-862
[2]   Nitinol - Its use in vascular surgery and other applications [J].
Barras, CDJ ;
Myers, KA .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2000, 19 (06) :564-569
[3]  
Bos GW, 1999, J BIOMED MATER RES, V47, P279, DOI 10.1002/(SICI)1097-4636(19991205)47:3<279::AID-JBM1>3.0.CO
[4]  
2-W
[5]   EFFECT OF HEPARIN ON VASCULAR SMOOTH-MUSCLE CELLS .1. CELL-METABOLISM [J].
CASTELLOT, JJ ;
COCHRAN, DL ;
KARNOVSKY, MJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 1985, 124 (01) :21-28
[6]   BIOCOMPATIBILITY OF NITINOL ALLOY AS AN IMPLANT MATERIAL [J].
CASTLEMAN, LS ;
MOTZKIN, SM ;
ALICANDRI, FP ;
BONAWIT, VL ;
JOHNSON, AA .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1976, 10 (05) :695-731
[7]  
DeScheerder I, 1997, CIRCULATION, V95, P1549
[8]   Closure of patent foramen ovale for paradoxical emboli: Intermediate-term risk of recurrent neurological events following transcatheter device placement [J].
Hung, J ;
Landzberg, MJ ;
Jenkins, KJ ;
King, MEE ;
Lock, JE ;
Palacios, IF ;
Lang, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (05) :1311-1316
[9]   CULTURE OF HUMAN ENDOTHELIAL CELLS DERIVED FROM UMBILICAL VEINS - IDENTIFICATION BY MORPHOLOGIC AND IMMUNOLOGICAL CRITERIA [J].
JAFFE, EA ;
NACHMAN, RL ;
BECKER, CG ;
MINICK, CR .
JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (11) :2745-2756
[10]  
KARGES HE, 1994, ARZNEIMITTEL-FORSCH, V44-1, P793